STA Pharma completes clinical supply of PhoenixMD’s breast cancer treatment

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/kritchanut)
(Image: Getty/kritchanut)

Related tags: STA pharma, WuXi STA, Breast cancer, Clinical trial, Metastatic breast cancer, HER2, Gmp

Clinical trial supply for the first targeted treatment of triple-negative breast cancer completed through PhoenixMD and STA Pharmaceutical agreement.

The drug candidate from Phoenix Molecular Designs, PMD-026, the first RSK inhibitor therapy for triple-negative breast cancer (TNBC), will enter the clinic in an upcoming Phase I/Ib study in women with breast cancer in the third quarter of 2019. The drug will also enter a toxicology study for investigational new drug (IND) application purposes.

STA Pharmaceutical, a subsidiary of WuXI STA, completed the manufacturing of the clinical supply of the drug product after the two companies entered an agreement in March 2018. STA produced a multi-kg drug supply of the candidate under good manufacturing practices (GMP) practices which is sufficient to treat all patients in the clinical trial.

The collaboration, which PhoenixMD said was a critical part of advancing the drug candidate to the clinic, will continue as WuXi STA recently expanded its operations in the US to include capsule production under GMP regulatory compliance.  

According to Sandra Dunn, CEO of PhoenixMD, metastatic TNBC, for which PMD-026 is a treatment, is the most deadly type of breast cancer. She added that PMD-026 is the first drug to ever reach clinical use against this novel target.

As a ribosomal S6 kinase (RSK) inhibitor therapy, PMD-026 works on the kinase protein that drives the growth of the breast cancer subtype relative to the hormone positive or HER-2 positive breast cancer. The company stated that the candidate is also applicable to greater than 14 different types of cancers.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

Flow Cytometry Services

Flow Cytometry Services

Q2 Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us

Products

View more

Webinars